|Systematic (IUPAC) name|
|Pregnancy cat.||B (US)|
|Legal status||Rx only (US)|
|Bioavailability||16% to 21% (dose-dependent)|
|Protein binding||60% to 70%|
|Half-life||1.7 ± 0.6 hours|
|Mol. mass||395.416 g/mol|
| (what is this?)
Cefdinir is a third generation oral cephalosporin antibiotic. It was discovered by Fujisawa Pharmaceutical Co., Ltd. "Fujisawa" (now Astellas) and introduced in 1991 under the brand name Cefzon. Warner-Lambert licensed this cephalosporin, cefdinir, for marketing in US from Fujisawa, Japan. Abbott obtained U.S. marketing rights to Omnicef (Cefdinir) in December 1998 through an agreement with Warner-Lambert Company. It was approved by FDA on Dec 4, 1997. It is available in US as Omnicef by Abbott Laboratories and in India as Cednir by Abbott and Cefdiel by Ranbaxy.
Mechanism of action
Therapeutic uses of cefdinir include otitis media, soft tissue infections, and respiratory tract infections, including sinusitis, strep throat, community-acquired pneumonia and acute exacerbations of bronchitis.
Side effects include diarrhea, vaginal infections or inflammation, nausea, headache, and abdominal pain."
Cefdinir is administered orally. It is available as capsules and a suspension. Dosage, schedule, and duration of therapy varies according to the type of infection.
"Blood" in the stool
The pediatric version of cefdinir can bind to iron in the digestive tract; in rare cases, this causes a rust or red discoloration of the stool. Blood typically appears dark brown or black in stool, and testing may confirm which is present.
If the reddish stool is accompanied by abdominal pain, weight loss, diarrhea, etc., a Clostridium difficile infection caused by the antibiotic could be signified.
Special caution required for pediatric dry powder: Dry powder may take longer for proper mixing
- PDF (399.4 KB). Drug Topics (May 26, 2009). Retrieved on July 24, 2009.
- "Omnicef capsules Patient Information". Abbott Laboratories. February 2004. Archived from the original on 2006-11-18. Retrieved 2006-11-24.